BR112015029401A2 - derivados pirazolo-pirrolidin-4-ona e seu uso no tratamento de doenças - Google Patents
derivados pirazolo-pirrolidin-4-ona e seu uso no tratamento de doençasInfo
- Publication number
- BR112015029401A2 BR112015029401A2 BR112015029401A BR112015029401A BR112015029401A2 BR 112015029401 A2 BR112015029401 A2 BR 112015029401A2 BR 112015029401 A BR112015029401 A BR 112015029401A BR 112015029401 A BR112015029401 A BR 112015029401A BR 112015029401 A2 BR112015029401 A2 BR 112015029401A2
- Authority
- BR
- Brazil
- Prior art keywords
- pyrazolo
- pyrrolidin
- diseases
- derivatives
- treatment
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4192—1,2,3-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Abstract
resumo patente de invenção: "derivados pirazolo-pirrolidin-4-ona e seu uso no tratamento de doenças". a presente invenção fornece um composto de fórmula (i) ou um sal farmaceuticamente aceitável do mesmo: (i) um método para fabricação dos compostos da invenção e seus usos terapêuticos. a presente invenção fornece ainda uma combinação de agentes farmacologicamente ativos e uma composição farmacêutica.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP13169441 | 2013-05-28 | ||
PCT/IB2014/061736 WO2014191906A1 (en) | 2013-05-28 | 2014-05-27 | Pyrazolo-pyrrolidin-4-one derivatives as bet inhibitors and their use in the treatment of disease |
Publications (2)
Publication Number | Publication Date |
---|---|
BR112015029401A2 true BR112015029401A2 (pt) | 2017-07-25 |
BR112015029401A8 BR112015029401A8 (pt) | 2020-03-17 |
Family
ID=48470849
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112015029401A BR112015029401A8 (pt) | 2013-05-28 | 2014-05-27 | derivados de pirazolo-pirrolidin-4-ona, seus usos, e composição e combinação farmacêuticas |
Country Status (14)
Country | Link |
---|---|
US (1) | US9624247B2 (pt) |
EP (1) | EP3004108B1 (pt) |
JP (1) | JP2016520118A (pt) |
KR (1) | KR20160012195A (pt) |
CN (1) | CN105263934B (pt) |
AU (1) | AU2014272695B2 (pt) |
BR (1) | BR112015029401A8 (pt) |
CA (1) | CA2912986A1 (pt) |
EA (1) | EA028175B1 (pt) |
ES (1) | ES2656471T3 (pt) |
MX (1) | MX2015016421A (pt) |
PL (1) | PL3004108T3 (pt) |
PT (1) | PT3004108T (pt) |
WO (1) | WO2014191906A1 (pt) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PE20151990A1 (es) | 2013-03-15 | 2016-01-13 | Incyte Corp | Heterociclos triciclicos como inhibidores de la proteina bet |
EA028175B1 (ru) | 2013-05-28 | 2017-10-31 | Новартис Аг | Производные пиразолопирролидин-4-она в качестве ингибиторов вет и их применение при лечении заболевания |
US9290514B2 (en) | 2013-07-08 | 2016-03-22 | Incyte Holdings Corporation | Tricyclic heterocycles as BET protein inhibitors |
US9315501B2 (en) | 2013-11-26 | 2016-04-19 | Incyte Corporation | Bicyclic heterocycles as BET protein inhibitors |
WO2015081203A1 (en) | 2013-11-26 | 2015-06-04 | Incyte Corporation | Bicyclic heterocycles as bet protein inhibitors |
US9309246B2 (en) | 2013-12-19 | 2016-04-12 | Incyte Corporation | Tricyclic heterocycles as BET protein inhibitors |
CR20160542A (es) | 2014-04-23 | 2017-04-25 | Incyte Corp | 1 H-PIRROLO[2,3-c]PIRIDIN-7(6H)-ONAS YPIRAZOLO[3,4-c]PlRIDIN-7(6H)-ONAS COMO INHIBIDORES DE PROTEINAS BET |
JP6599979B2 (ja) | 2014-09-15 | 2019-10-30 | インサイト・コーポレイション | Betタンパク質阻害剤として用いるための三環式複素環化合物 |
GB201504694D0 (en) | 2015-03-19 | 2015-05-06 | Glaxosmithkline Ip Dev Ltd | Covalent conjugates |
TW201722966A (zh) | 2015-10-29 | 2017-07-01 | 英塞特公司 | Bet蛋白質抑制劑之非晶固體形式 |
CN109153647A (zh) | 2016-02-15 | 2019-01-04 | 分子医学研究中心责任有限公司 | 用于治疗癌症的taf1抑制剂 |
CA3220957A1 (en) | 2016-06-20 | 2017-12-28 | Incyte Corporation | Crystalline solid forms of a bet inhibitor |
AU2017359288A1 (en) | 2016-11-14 | 2019-05-30 | Cemm - Forschungszentrum Für Molekulare Medizin Gmbh | Combination of a BRD4 inhibitor and an antifolate for the therapy of cancer |
CN111712496B (zh) | 2017-12-20 | 2023-05-02 | 贝达药业股份有限公司 | 作为溴结构域蛋白质抑制剂的化合物和组合物 |
US20210038661A1 (en) * | 2018-03-05 | 2021-02-11 | Klinikum Rechts Der Isar Der Technischen Universität München | Treatment of tumors by a combination of an oncolytic adenovirus and a cdk4/6 inhibitor |
WO2021009068A1 (en) * | 2019-07-12 | 2021-01-21 | Scenic Immunology B.V. | N-substituted-3,4-(fused 5-ring)-5-phenyl-pyrrolidine-2-one compounds as inhibitors of isoqc and/or qc enzyme |
US11833155B2 (en) | 2020-06-03 | 2023-12-05 | Incyte Corporation | Combination therapy for treatment of myeloproliferative neoplasms |
Family Cites Families (75)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3829420A (en) | 1970-07-13 | 1974-08-13 | Sumitomo Chemical Co | 3,4-dihydro-2(1h)-quinazolinones and preparation thereof |
US4099002A (en) | 1970-12-23 | 1978-07-04 | Sumitomo Chemical Company, Limited | Quinazolinone derivatives and a process for production thereof |
JPS4822715B1 (pt) | 1970-12-28 | 1973-07-07 | ||
JPS5427356B2 (pt) | 1972-03-31 | 1979-09-10 | ||
US4258187A (en) | 1977-06-16 | 1981-03-24 | E. I. Du Pont De Nemours And Company | Process for preparing quinazolinone oxides |
US4335127A (en) | 1979-01-08 | 1982-06-15 | Janssen Pharmaceutica, N.V. | Piperidinylalkyl quinazoline compounds, composition and method of use |
JPS5721388A (en) | 1980-07-11 | 1982-02-04 | Nippon Nohyaku Co Ltd | Condensed pyrazole derivative |
DE3420799A1 (de) | 1984-06-04 | 1985-12-05 | Bayer Ag, 5090 Leverkusen | Chromogene 4,4-diaryl-dihydrochinazolone, ihre herstellung und verwendung |
AU2436792A (en) | 1991-08-16 | 1993-03-16 | Merck & Co., Inc. | Quinazoline derivatives as inhibitors of hiv reverse transcriptase |
US5508300A (en) | 1994-01-14 | 1996-04-16 | Pfizer Inc. | Dihydro pyrazolopyrroles, compositions and use |
NZ333609A (en) | 1996-07-05 | 2000-08-25 | Cancer Res Campaign Tech | Peptide inhibitors of the interaction between P35 and MDM2 and the treatment of tumor cells |
HRP980143A2 (en) | 1997-04-09 | 1999-02-28 | Soo Sung Ko | 4,4-disubstituted-3,4-dihydro-2 (1h)-quinazolinones useful as hiv reverse transcriptase inhibitors |
WO2000066560A1 (en) | 1999-05-04 | 2000-11-09 | American Home Products Corporation | Quinazolinone and benzoxazine derivatives as progesterone receptor modulators |
JP2001302515A (ja) | 2000-04-18 | 2001-10-31 | Sumitomo Pharmaceut Co Ltd | ポリ(adp−リボース)ポリメラーゼ阻害剤 |
US6479499B1 (en) | 2000-06-28 | 2002-11-12 | National Science Council | 2-phenyl-4-quinazolinone compounds, 2-phenyl-4-alkoxy-quinazoline compounds and their pharmaceutical compositions |
NZ524475A (en) | 2000-08-10 | 2004-11-26 | Pharmacia Italia S | Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them |
DE60225719T2 (de) | 2001-12-18 | 2009-04-23 | F. Hoffmann-La Roche Ag | Cis-2,4,5- triphenyl-imidazoline und ihre verwendung bei der behandlung von tumoren |
JP2005519915A (ja) | 2002-01-18 | 2005-07-07 | セレテック・リミテッド・ライアビリティ・カンパニー | Edg受容体に関連する症状の処置方法 |
WO2003095625A2 (en) | 2002-05-13 | 2003-11-20 | 3-Dimensional Pharmaceuticals, Inc. | Method for cytoprotection through mdm2 and hdm2 inhibition |
US7119111B2 (en) | 2002-05-29 | 2006-10-10 | Amgen, Inc. | 2-oxo-1,3,4-trihydroquinazolinyl derivatives and methods of use |
WO2004014916A1 (en) | 2002-08-13 | 2004-02-19 | Warner-Lambert Company Llc | Pyrimidine fused bicyclic metalloproteinase inhibitors |
JP2007524596A (ja) | 2003-02-28 | 2007-08-30 | トランスフォーム・ファーマシューティカルズ・インコーポレイテッド | 共結晶医薬組成物 |
US7145012B2 (en) | 2003-04-23 | 2006-12-05 | Pfizer Inc. | Cannabinoid receptor ligands and uses thereof |
US20040214856A1 (en) | 2003-04-23 | 2004-10-28 | Pfizer Inc | Cannabinoid receptor ligands and uses thereof |
US20040213264A1 (en) | 2003-04-25 | 2004-10-28 | Nortel Networks Limited | Service class and destination dominance traffic management |
WO2005019188A1 (ja) | 2003-08-22 | 2005-03-03 | Takeda Pharmaceutical Company Limited | 縮合ピリミジン誘導体およびその用途 |
US20100087413A1 (en) | 2003-09-22 | 2010-04-08 | Thomas Wilckens | Prevention and treatment of inflammation-induced and/or immune-mediated bone loss |
ES2376552T3 (es) | 2003-11-25 | 2012-03-14 | Novartis Ag | Compuestos de quinazolinona como agentes antic�?ncer. |
ES2314660T3 (es) | 2004-05-18 | 2009-03-16 | F. Hoffmann-La Roche Ag | Nuevas cis-imidazolinas. |
US8178545B2 (en) | 2004-06-01 | 2012-05-15 | University Of Virginia Patent Foundation | Dual small molecule inhibitors of cancer and angiogenesis |
GB0419481D0 (en) | 2004-09-02 | 2004-10-06 | Cancer Rec Tech Ltd | Isoindolin-1-one derivatives |
US20060069085A1 (en) | 2004-09-28 | 2006-03-30 | Rulin Zhao | Preparation of 4,5-dihydro-pyrazolo[3,4-c]pyrid-2-ones |
CA2589830A1 (en) | 2005-01-05 | 2006-07-13 | Rigel Pharmaceuticals, Inc. | Ubiquitin ligase inhibitors |
WO2006097337A2 (en) | 2005-03-18 | 2006-09-21 | Onepharm Gmbh | 11β-HYDROXYSTEROID DEHYDROGENASES |
WO2006100038A1 (en) | 2005-03-23 | 2006-09-28 | Syngenta Participations Ag | Triazolopyrimidine derivatives useful as fungicides |
US7576082B2 (en) | 2005-06-24 | 2009-08-18 | Hoffman-La Roche Inc. | Oxindole derivatives |
US7968583B2 (en) | 2005-12-12 | 2011-06-28 | Nerviano Medical Sciences S.R.L. | Substituted pyrrolo-pyrazole derivatives active as kinase inhibitors |
WO2007096334A1 (en) | 2006-02-24 | 2007-08-30 | Pfizer Italia Srl | Pyrrolopyrrolones active as kinase inhibitors |
DE102006016426A1 (de) | 2006-04-07 | 2007-10-11 | Merck Patent Gmbh | Neuartige Cyclobutyl-Verbindungen als Kinase-Inhibitoren |
WO2007144384A1 (en) | 2006-06-14 | 2007-12-21 | 4Sc Ag | Pyrazolopyrimidones |
US8222288B2 (en) | 2006-08-30 | 2012-07-17 | The Regents Of The University Of Michigan | Small molecule inhibitors of MDM2 and the uses thereof |
WO2008034039A2 (en) | 2006-09-15 | 2008-03-20 | Nexuspharma Inc. | Novel tetrahydro-isoquinolines |
WO2008045529A1 (en) | 2006-10-12 | 2008-04-17 | Serenex, Inc. | Purine and pyrimidine derivatives for treatment of cancer and inflammatory diseases |
CA2682473A1 (en) | 2007-03-30 | 2008-10-09 | Shionogi & Co., Ltd. | Novel pyrrolinone derivative and pharmaceutical composition comprising the same |
WO2008130614A2 (en) | 2007-04-20 | 2008-10-30 | University Of Pittsburg-Of The Commonwealth System Of Higher Education | Selective and dual-action p53/mdm2/mdm4 antagonists |
CA2709784A1 (en) | 2007-12-21 | 2009-07-09 | University Of Rochester | Method for altering the lifespan of eukaryotic organisms |
UY31982A (es) | 2008-07-16 | 2010-02-26 | Boehringer Ingelheim Int | Derivados de 1,2-dihidropiridin-3-carboxamidas n-sustituidas |
WO2010035727A1 (ja) | 2008-09-25 | 2010-04-01 | 塩野義製薬株式会社 | 新規ピロリノン誘導体およびそれを含有する医薬組成物 |
JP2012505231A (ja) | 2008-10-08 | 2012-03-01 | ブリストル−マイヤーズ スクイブ カンパニー | アゾロピロロンメラニン凝集ホルモン受容体−1アンタゴニスト |
US9040508B2 (en) | 2008-12-08 | 2015-05-26 | Vm Pharma Llc | Compositions of protein receptor tyrosine kinase inhibitors |
WO2010141738A2 (en) | 2009-06-03 | 2010-12-09 | President And Fellows Of Harvard College | Compositions and method for inhibiting tumor growth |
GB0919423D0 (en) * | 2009-11-05 | 2009-12-23 | Glaxosmithkline Llc | Novel compounds |
CU24130B1 (es) | 2009-12-22 | 2015-09-29 | Novartis Ag | Isoquinolinonas y quinazolinonas sustituidas |
US8440693B2 (en) | 2009-12-22 | 2013-05-14 | Novartis Ag | Substituted isoquinolinones and quinazolinones |
ES2526671T3 (es) | 2010-06-22 | 2015-01-14 | Glaxosmithkline Llc | Compuestos de benzotriazoldiazepina inhibidores de bromodominios |
US20120065210A1 (en) | 2010-09-15 | 2012-03-15 | Xin-Jie Chu | Substituted hexahydropyrrolo[1,2-c]imidazolones |
GB201016880D0 (en) * | 2010-10-07 | 2010-11-17 | Riotech Pharmaceuticals Ltd | Phosphodiesterase inhibitors |
NZ611866A (en) | 2010-11-12 | 2015-04-24 | Univ Michigan | Spiro-oxindole mdm2 antagonists |
AR084070A1 (es) * | 2010-12-02 | 2013-04-17 | Constellation Pharmaceuticals Inc | Inhibidores del bromodominio y usos de los mismos |
EP2705039B1 (en) * | 2011-05-04 | 2017-07-26 | Constellation Pharmaceuticals, Inc. | Bromodomain inhibitors and uses thereof |
WO2012174487A2 (en) * | 2011-06-17 | 2012-12-20 | Constellation Pharmaceuticals, Inc. | Bromodomain inhibitors and uses thereof |
US8859535B2 (en) | 2011-06-20 | 2014-10-14 | Novartis Ag | Hydroxy substituted isoquinolinone derivatives |
EP2721007B1 (en) | 2011-06-20 | 2015-04-29 | Novartis AG | Cyclohexyl isoquinolinone compounds |
WO2013027168A1 (en) | 2011-08-22 | 2013-02-28 | Pfizer Inc. | Novel heterocyclic compounds as bromodomain inhibitors |
WO2013033268A2 (en) | 2011-08-29 | 2013-03-07 | Coferon, Inc. | Bivalent bromodomain ligands, and methods of using same |
JP5992054B2 (ja) | 2011-11-29 | 2016-09-14 | ノバルティス アーゲー | ピラゾロピロリジン化合物 |
WO2013097052A1 (en) | 2011-12-30 | 2013-07-04 | Abbott Laboratories | Bromodomain inhibitors |
UY34591A (es) | 2012-01-26 | 2013-09-02 | Novartis Ag | Compuestos de imidazopirrolidinona |
US20130281397A1 (en) | 2012-04-19 | 2013-10-24 | Rvx Therapeutics Inc. | Treatment of diseases by epigenetic regulation |
US20130281396A1 (en) | 2012-04-19 | 2013-10-24 | Rvx Therapeutics Inc. | Treatment of diseases by epigenetic regulation |
US20130281399A1 (en) | 2012-04-19 | 2013-10-24 | Rvx Therapeutics Inc. | Treatment of diseases by epigenetic regulation |
EP2838881B1 (en) | 2012-04-20 | 2018-08-08 | AbbVie Inc. | Isoindolone derivatives |
US9365576B2 (en) | 2012-05-24 | 2016-06-14 | Novartis Ag | Pyrrolopyrrolidinone compounds |
US8975417B2 (en) * | 2013-05-27 | 2015-03-10 | Novartis Ag | Pyrazolopyrrolidine derivatives and their use in the treatment of disease |
EA028175B1 (ru) | 2013-05-28 | 2017-10-31 | Новартис Аг | Производные пиразолопирролидин-4-она в качестве ингибиторов вет и их применение при лечении заболевания |
-
2014
- 2014-05-27 EA EA201592255A patent/EA028175B1/ru not_active IP Right Cessation
- 2014-05-27 BR BR112015029401A patent/BR112015029401A8/pt not_active Application Discontinuation
- 2014-05-27 PT PT147283501T patent/PT3004108T/pt unknown
- 2014-05-27 ES ES14728350.1T patent/ES2656471T3/es active Active
- 2014-05-27 US US14/892,623 patent/US9624247B2/en not_active Expired - Fee Related
- 2014-05-27 CA CA2912986A patent/CA2912986A1/en not_active Abandoned
- 2014-05-27 AU AU2014272695A patent/AU2014272695B2/en not_active Ceased
- 2014-05-27 KR KR1020157036224A patent/KR20160012195A/ko not_active Application Discontinuation
- 2014-05-27 MX MX2015016421A patent/MX2015016421A/es unknown
- 2014-05-27 CN CN201480030590.0A patent/CN105263934B/zh not_active Expired - Fee Related
- 2014-05-27 WO PCT/IB2014/061736 patent/WO2014191906A1/en active Application Filing
- 2014-05-27 PL PL14728350T patent/PL3004108T3/pl unknown
- 2014-05-27 EP EP14728350.1A patent/EP3004108B1/en not_active Not-in-force
- 2014-05-27 JP JP2016516280A patent/JP2016520118A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
ES2656471T3 (es) | 2018-02-27 |
MX2015016421A (es) | 2016-03-03 |
AU2014272695B2 (en) | 2016-10-20 |
US20160102107A1 (en) | 2016-04-14 |
CN105263934A (zh) | 2016-01-20 |
PL3004108T3 (pl) | 2018-03-30 |
EP3004108A1 (en) | 2016-04-13 |
AU2014272695A1 (en) | 2015-11-26 |
EA201592255A1 (ru) | 2016-04-29 |
PT3004108T (pt) | 2018-01-24 |
KR20160012195A (ko) | 2016-02-02 |
CA2912986A1 (en) | 2014-12-04 |
EA028175B1 (ru) | 2017-10-31 |
US9624247B2 (en) | 2017-04-18 |
BR112015029401A8 (pt) | 2020-03-17 |
CN105263934B (zh) | 2017-09-08 |
WO2014191906A1 (en) | 2014-12-04 |
EP3004108B1 (en) | 2017-10-18 |
JP2016520118A (ja) | 2016-07-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112015029512A8 (pt) | derivados de pirazolopirrolidina, seus usos, e composição e combinação farmacêuticas | |
BR112015029401A2 (pt) | derivados pirazolo-pirrolidin-4-ona e seu uso no tratamento de doenças | |
BR112015029491A2 (pt) | derivados de imidazopirrolidinona e seu uso no tratamento de doença | |
BR112015016911A2 (pt) | tiadiazol, análogos dos mesmos e métodos de tratamento de condições relacionadas à deficiência de smn | |
BR112015029353A2 (pt) | derivados de pirazolo-pirrolidin-4-ona e seu uso no tratamento de doenças | |
BR112014032734A2 (pt) | derivados de pirrolidina e seu uso como moduladores da série de reação de complemento | |
BR112013026257A2 (pt) | derivados de glicosídeo e usos dos mesmos para o tratamento de diabetes | |
BR112015007366A2 (pt) | derivados de acilaminopirimidina para o tratamento de infecções virais e outras doenças | |
BR112015019369A2 (pt) | derivados de ácido bisfenil butanóico substituídos como inibidores de nep (endopeptidase neutra) | |
BR112019005318A2 (pt) | compostos de aza-indazol para uso em lesões no tendão e/ou ligamento | |
BR112015019412A8 (pt) | inibidores de bace1, seus usos, e composição farmacêutica | |
BR112013026361A2 (pt) | derivados de glicosídeo e usos dos mesmos | |
BR112016026552A8 (pt) | derivados de carboxamida, seus usos, composição farmacêutica, e combinação | |
BR112015014433A2 (pt) | compostos tricíclicos | |
BR112015014292A2 (pt) | compostos tricíclicos para inibição do canal de cftr | |
BR112019007863A2 (pt) | derivados de naftiridinona inovadores e seu uso no tratamento de arritmia | |
BR112014004732A2 (pt) | composto benzotiazolona | |
BR112012020377A2 (pt) | utilização de um ou mais selecionado do grupo constituído por um composto da fórmula (i), uma mistura racêmica-diastereomérica e um isômero óptico do referido composto, e um sal farmaceuticamente aceitável e uma pródroga do mesmo, método, composição farmacêutica e kit para tratamento de caquexia e embalagem comercial | |
BR112019005578A2 (pt) | compostos de indazol para uso em lesões no tendão e/ou ligamento | |
BR112019024804A2 (pt) | compostos bicíclicos 5,6-fundidos e composições para o tratamento de doenças parasíticas | |
EA201691058A1 (ru) | Производные пирролопирролона и их применение для лечения заболеваний | |
BR112014030288A8 (pt) | composição farmacêutica, uso da mesma, e, uso de metanossulfonilacetonitrila | |
BR112015012497A8 (pt) | combinações e composições farmacêuticas, seus usos, preparação combinada, e embalagem comercial | |
BR112015019307A2 (pt) | derivados de ácido butanoico substituído com bisfenila como inibidores de nep com eficácia in vivo melhorada | |
BR112018072183A2 (pt) | composição farmacêutica, e, método para prevenir uma doença de pele |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B07E | Notice of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements | ||
B350 | Update of information on the portal [chapter 15.35 patent gazette] |